Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome
NCT03205995 · aHUS Phase 3Terminated
- Lead sponsor
- Omeros Corporation (Industry)
- Enrollment
- 6 (actual)
- Start date
- 2 May 2018
- Primary completion
- 2 Feb 2021 (actual)
- Study completion
- 2 Feb 2021
- Last update posted
- 10 Dec 2025
Design
- Study type
- Interventional
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None
- Arms
- 1
Interventions
- OMS721 (narsoplimab) Biological
Conditions and primary outcome
- Thrombotic Microangiopathies
- Atypical Hemolytic Uremic Syndrome
Primary outcome
Platelet Count (10^9 Platelets/L) Change From Baseline at Week 26 (Week 26)
Posted results on ClinicalTrials.gov
Source: ClinicalTrials.gov results for NCT03205995 (opens in a new tab)· Licence: public-domain
First posted · Last update posted · Imported from ClinicalTrials.gov download 2026-10-25
Primary outcomes with a statistical analysis
No primary outcome with a statistical analysis is posted for this study.
Serious adverse events
Time frame: From Day 1 to Final Study Visit (up to Day 771)
| Group | Affected | At risk |
|---|---|---|
| OMS721 (Narsoplimab) | 5 | 6 |
Posted results as ClinicalTrials.gov prints them: primary outcome analyses and serious adverse event totals only. Registry facts, not reviewed by HealthTrade and not investment advice; filing-derived results are listed separately.
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Results from company and journal sources
No editor-confirmed results are on record for this study.
Publications
1 on PubMedInterventions for atypical haemolytic uraemic syndrome.
The Cochrane database of systematic reviews · 2021 Mar 23
PubMed 33783815 (opens in a new tab)DOI 10.1002/14651858.CD012862.pub2 (opens in a new tab)
Citations from PubMed, U.S. National Library of Medicine; abstracts are not stored. A publication lists this study’s NCT number and may be a review that cites many studies.
CT-VCA trial quality
About CT-VCALoading CT-VCA scores…
Data integrity
Compare what the registry, company releases, FDA documents and publications say about this study.
Drugs on HealthTrade
Source
- NCT03205995 on ClinicalTrials.gov (opens in a new tab) Licence: public-domain. Read
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Listing a study does not mean NLM has evaluated it.
Nothing on this page is medical or investment advice.